Gantt Chart for Clean Room Construction Projects

A clean room is not a building -- it is an air handling system with walls around it. Every design decision, every construction detail, and every commissioning step exists to achieve and maintain a defined particle count per cubic meter of air. This makes clean room construction the most technically demanding facility type in commercial construction, and the most schedule-sensitive: a single contamination event during commissioning can require weeks of investigation, remediation, and retesting before the facility can advance to the next phase.

Clean room projects span a wide range of applications. Pharmaceutical sterile fill-finish requires ISO 5 classification and full cGMP (current Good Manufacturing Practice) compliance. Aerospace component manufacturing requires ISO 7 with ESD (electrostatic discharge) control. Medical device assembly operates at ISO 7-8. Each application has its own regulatory framework, design standards, and qualification requirements -- but the construction and Gantt chart structure share common phases.

Major pharmaceutical manufacturing facilities and biologic drug production facilities take 3-6 years from site selection to product release. This guide covers a mid-scale pharmaceutical or biotech facility -- a primary processing building with ISO 5 fill-finish, ISO 7 support areas, and a full cGMP qualification program.

ISO Classification and Application Requirements

ISO 14644-1 is the international standard for clean room classification. It defines clean room classes by particle count per cubic meter of air at specified particle sizes:

|---|---|---|---|

| ISO 1 | 10 | Class 1 | Advanced semiconductor (EUV lithography) |

| ISO 3 | 1,000 | Class 1 | Research, specialized optics |

| ISO 5 | 3,520 | Class 100 | Sterile pharmaceutical fill-finish, aseptic processing |

| ISO 6 | 35,200 | Class 1,000 | Cleanroom garment laundering, some device assembly |

| ISO 7 | 352,000 | Class 10,000 | Pharmaceutical gowning, packaging, device assembly |

| ISO 8 | 3,520,000 | Class 100,000 | Component preparation, less critical processes |

Pharmaceutical and biotech manufacturing must comply with FDA 21 CFR Parts 210/211 (drug manufacturing cGMP) and, for facilities serving European markets, EU GMP Annex 1 (2023 edition). The 2023 Annex 1 revision significantly expanded requirements, adding a mandatory Contamination Control Strategy (CCS) document that describes how the facility design prevents contamination at every step. Facilities undergoing FDA Pre-Approval Inspection (PAI) before an NDA (New Drug Application) or BLA (Biologics License Application) approval cannot begin commercial manufacturing until FDA issues a favorable PAI determination.

Aerospace clean rooms for optical, guidance, and sensor components operate under customer and program-specific standards (often derived from MIL-STD-1246 for product cleanliness and IEST-RP-CC012 for clean room operations).

Medical device clean rooms fall under FDA 21 CFR Part 820 (Quality System Regulation / QSR) or, for EU markets, EU MDR/IVDR with ISO 13485 quality system requirements.

Phase-by-Phase Gantt Chart

Phase 1: Concept and Feasibility (Months 1-4)

Clean room construction begins with a process definition that drives every other decision. The pharmaceutical or biotech client defines: product type (small molecule drug, biologic, combination product), dosage form (injectable liquid, lyophilized powder, topical, inhaled), production volume (batch size and annual batches), and regulatory targets (which markets -- FDA, EMA, PMDA -- and whether a cGMP PAI is required for a specific product approval).

These decisions determine the ISO classification required, the airflow strategy (unidirectional vs. turbulent), the environmental monitoring program (viable and non-viable particle sampling, temperature, humidity, pressure), and the equipment list (fill-finish equipment, isolators, RABS (restricted access barrier systems), lyophilizers, autoclave, CIP/SIP systems).

The feasibility study produces a process flow diagram, a room classification matrix (every room with its ISO class, gowning requirement, and pressure differential target), and a preliminary equipment list. These documents drive the building footprint.

Gantt tasks: process definition workshops, regulatory strategy assessment, room classification matrix, process flow diagram, equipment list and layout concept, preliminary capital cost estimate, site selection.

Phase 2: Basic Design (Months 3-9)

Basic design (also called conceptual engineering or FEED -- Front-End Engineering and Design) develops the process and utility design to 30-40% completion. This is the phase where all major decisions are made: building layout, HVAC strategy, utility systems, and equipment configuration.

HVAC design -- the central engineering challenge. Clean room HVAC is not a conventional system. The key parameters:

Air change rates (ACH -- air changes per hour). ISO 5 pharmaceutical fill-finish requires 240-480 ACH. ISO 7 support areas require 60-90 ACH. For comparison, a conventional office building runs 6-10 ACH. These high air change rates require massive airflow volumes delivered through HEPA filter banks covering 15-25% of the ceiling area.

Unidirectional airflow. In ISO 5 critical zones, air must move in parallel streams (laminar flow) from ceiling HEPA filters to the floor or raised perforated floor panels at a velocity of 90 feet per minute (±20%). Any turbulence creates particle mixing. Every piece of equipment, every person, and every piping penetration is a potential turbulence generator -- the layout must be designed to minimize this.

Pressurization cascade. Clean core areas are maintained at the highest positive pressure relative to atmospheric. Adjacent areas step down in a cascade: ISO 5 (+15 Pa) → ISO 7 (+12.5 Pa) → ISO 8 (+10 Pa) → corridor → outside. This cascade prevents contaminated air from migrating into cleaner areas when doors open. Maintaining the cascade under all operating conditions (doors opening, equipment operating, filter loading) requires careful HVAC control design and validated pressure monitoring.

100% outside air. Pharmaceutical clean rooms do not recirculate air. All exhaust air is discharged and replaced with conditioned outside air. In cold or hot climates, this is a major energy cost and a major HVAC equipment sizing driver.

Temperature and humidity control. ISO 5 sterile manufacturing targets 18-22°C and 30-50% RH (low humidity reduces microbial growth and electrostatic discharge risk). These tight ranges require precision humidity control -- steam humidification and refrigerant-based dehumidification operating together.

Materials. Every surface in a cGMP clean room must be cleanable, non-shedding, non-reactive, and able to withstand cleaning agents (IPA, hydrogen peroxide vapor, peracetic acid). Standard materials: 316L stainless steel for process contact surfaces and equipment frames; electropolished stainless for injectable drug product contact; epoxy flooring with integral coved base (no right-angle joints at floor-wall intersections where particles accumulate); painted (epoxy paint) or stainless-clad walls; flush doors with no threshold; clean-room-rated lighting fixtures (IP54 minimum) with no ledges.

Water for injection (WFI) and purified water (PW) systems. Injectable drug manufacturing requires WFI (Water for Injection, meeting USP <1231>) for all product contact operations. WFI is produced by distillation from purified water. The distribution system is passivated 316L stainless steel, continuously circulating at 65°C or greater (to prevent microbial growth), with no dead legs. The WFI system is one of the longest design and validation cycles in the project -- typically 18-24 months from design through commissioning and qualification.

Gantt tasks: HVAC design, water system design, electrical and instrumentation design, equipment layout, building structure and skin design, utility requirements, 30% design review.

Phase 3: Detailed Design (Months 8-18)

Detailed design develops all engineering to construction-ready completeness (100%). For pharmaceutical facilities, this phase produces:

Piping and instrumentation diagrams (P&IDs) for every process and utility system
Isometric drawings for all piping
HVAC duct routing, filter bank locations, diffuser schedules
Electrical single-line diagrams, panel schedules, instrument wiring diagrams
Validation documentation plan (DQ -- Design Qualification)
Equipment procurement specifications (functional specifications, user requirements specifications)
Construction specifications

The DQ (Design Qualification) is the first of the IQ/OQ/PQ validation documents. It verifies that the design meets user requirements and cGMP regulations. DQ is reviewed and approved before procurement commitments are made for GMP-critical equipment.

Long-lead procurement during detailed design. Critical long-lead items must be ordered as specifications are finalized -- do not wait for the complete design package:

Process equipment (filling lines, lyophilizers, autoclaves): 40-60 week lead time
Clean room HVAC air handling units: 20-30 week lead time
HEPA filter banks: 12-16 week lead time
WFI and purified water systems: 30-40 week lead time
Isolators and RABS: 40-52 week lead time
Process instrumentation (flow meters, pressure transmitters, temperature sensors): 10-16 week lead time

Gantt tasks: P&ID development, 60% design review, equipment functional specifications, long-lead equipment orders, 90% design review, 100% design package issue, DQ completion.

Phase 4: Permitting (Months 12-18, concurrent with detailed design)

Building permit. Clean room facilities involve specialized systems (HVAC, process piping, high-purity water) that require detailed review. In some jurisdictions, the clean room HVAC system requires a separate mechanical permit and a commissioning plan submitted to the building department. Anticipate one round of plan check comments and 8-12 weeks for permit issuance.

FDA Pre-Submission Meetings (Type B or C meetings). For pharmaceutical facilities supporting a specific NDA or BLA, the FDA pre-approval inspection cannot begin until the facility is qualified and a PAI has been requested. However, a pre-submission meeting with FDA before construction begins to align on process design and facility layout can prevent costly late-stage design changes. These meetings take 3-6 months to schedule and receive FDA feedback.

State pharmaceutical manufacturing licenses. Most states require a pharmaceutical manufacturer's license from the state board of pharmacy or department of health. Applications typically require submission of facility design information and are reviewed after the facility is built and a federal cGMP registration is obtained (21 CFR Part 207 -- Drug Establishment Registration).

Environmental permits. Clean room HVAC exhaust may trigger air quality permit requirements if it carries process solvents or volatile intermediates. WFI and process water discharge to municipal sewer requires a pretreatment permit in some jurisdictions.

Gantt tasks: building permit application, FDA pre-submission meeting request, state manufacturing license pre-application, environmental permit assessment, permit issuance.

Phase 5: Construction (Months 15-30)

Clean construction protocol. Standard construction generates particle counts millions of times above ISO 5 requirements. During construction, the building interior is not a clean room -- but the construction must be executed in a way that the building can be cleaned to clean room standards after construction. This means:

Progressive clean-up: each area is cleaned to a defined standard before the next trade begins work
Dust containment barriers between active construction and areas approaching completion
No open-top cutting of drywall, epoxy floor preparation done wet
Filters in HVAC systems replaced at commissioning (construction filters are sacrificial)
No dirty equipment (welding, grinding) in completed areas without containment protocols

Room-within-room construction for critical areas. ISO 5 fill-finish suites are sometimes constructed as separate enclosed structures within the building shell, with their own isolated structural system to minimize vibration transmission from building systems.

Flooring. Epoxy flooring in clean rooms is installed in multiple layers: substrate preparation, primer coat, broadcast anti-static aggregate (if ESD control required), epoxy base coat, epoxy top coat. The integral coved base (flooring that curves up the wall to 4 inches) eliminates the floor-wall joint. Total process: 7-10 days per area, with cure time between coats that requires coordination with other trades.

Piping. Process piping (stainless, high-purity plastic) is fabricated and installed to orbital weld standards for pharmaceutical applications. Orbital welding (automated TIG welding of 316L stainless using a closed welding head) produces consistent, validated weld quality that can be borescope-inspected and documented. Orbital weld logs are required for cGMP qualification.

HVAC installation. Clean room HVAC ducts are cleaned before installation (swabbed internally), sealed with plastic caps, and inspected. No bare sheet metal in pharmaceutical clean rooms -- all ductwork uses factory-insulated and internally smooth duct or spiral round duct with external insulation.

Gantt tasks: site work and foundation, structural steel, building skin, interior framing, flooring, stainless and process piping, HVAC ductwork, electrical and instrumentation, equipment installation (process equipment, WFI/PW system, HVAC AHUs), HEPA filter bank installation, door and window installation, finishes.

Phase 6: Commissioning and Qualification (Months 28-42)

This phase is unique to cGMP facilities and represents 30-40% of total project duration. It cannot be accelerated without regulatory risk.

Commissioning. Commissioning verifies that all systems operate as designed. The clean room HVAC system is commissioned first:

HEPA filter leak test (DOP/PAO challenge): each HEPA filter is integrity tested by injecting a challenge aerosol upstream and scanning for leaks with a photometer. Any filter with a detectable leak is replaced or repaired.
Airflow testing: velocity profiles at each supply diffuser, airflow visualization (smoke test to verify unidirectional flow pattern in ISO 5 zones), air change rate measurement per ISO 14644-3.
Pressurization test: room-by-room differential pressure measurement under all operating conditions including door opening.
Temperature and humidity uniformity: mapping tests at multiple points per ISO 14644-3.

Utilities are commissioned: WFI system (temperature, conductivity, TOC, endotoxin testing per USP <1231>), compressed gases (purity testing), nitrogen blanket systems.

IQ/OQ/PQ Qualification.

Installation Qualification (IQ): Verifies that equipment and systems are installed according to design specifications. Every instrument tag number is verified against the instrument list; every weld log is reviewed; every component is confirmed to be the specified model. For a medium pharmaceutical facility, IQ documentation fills multiple binders.

Operational Qualification (OQ): Verifies that equipment operates within design parameters across its operating range. HVAC OQ includes door-opening studies (does the pressure cascade maintain with one door open? Two?). Equipment OQ includes cycle development for autoclaves, lyophilizers, and filling lines.

Performance Qualification (PQ): Verifies that the system consistently performs in accordance with specifications under representative process conditions. PQ is run at production scale, with actual product or a qualified substitute.

Media fill (sterile manufacturing). The most critical qualification step for sterile fill-finish. A media fill simulates the full aseptic filling operation with microbiological growth media instead of drug product. Filled containers are incubated for 14 days. Any contaminated unit is a failure. FDA guidance requires 0 contaminated units out of a minimum 5,000 units (for processes with <5,000 units at risk), and rates ≤0.1% for larger fills. A failed media fill requires root cause investigation and one or more repeat fills before the process is validated.

Environmental monitoring (EM) qualification. Establishes the baseline particle and microbial count data for the facility and validates the EM sampling plan. Requires 3 consecutive months of data at or below classification limits.

Gantt tasks: HVAC commissioning, HEPA leak testing, airflow and pressurization testing, utility commissioning, WFI qualification, equipment IQ, equipment OQ, equipment PQ, environmental monitoring baseline, media fill #1, media fill #2 (if #1 fails or for process confirmation), process validation (3 consecutive production batches meeting all specifications).

Phase 7: Regulatory Submission and First Product (Months 40-48+)

For a pharmaceutical facility, commercial manufacturing cannot begin until:

All qualification documentation is complete and reviewed
The product NDA or BLA is approved by FDA (which includes review of the facility information submitted in the CMC section of the application)
FDA has conducted the Pre-Approval Inspection (PAI) and found no critical or major deficiencies
State manufacturing license is granted

The PAI is typically scheduled 2-6 months after the NDA/BLA submission's PDUFA date (the target action date). FDA inspectors review all validation documentation, inspect the facility, observe operations, and may collect samples. A Critical or Major finding at PAI results in a Complete Response Letter (CRL) delaying approval.

Gantt tasks: NDA/BLA submission (includes facility and process information), FDA PAI scheduling, PAI conduct, PAI response (if deficiencies), license approval, first commercial batch, batch release.

Clean Room Construction Gantt Chart Template

|---|---|---|---|

Managing Schedule Risk in Clean Room Projects

Validation documentation is a parallel workstream. IQ/OQ/PQ protocols must be written, reviewed, and approved before execution. A common failure mode: construction finishes on schedule, but qualification is delayed 3-6 months because the validation documentation was not written during construction. Assign a dedicated validation writer from the start of detailed design.

Media fill failures reset the clock. A single contaminated unit in a media fill investigation, root cause analysis, and repeat media fill adds 3-4 months. The most common root causes: technique errors by aseptic operators, HVAC anomalies, or equipment design deficiencies that allow contamination ingress. Identify and train your aseptic operators before the first media fill; conduct training fills before the qualification fill.

FDA PAI scheduling is not within the project team's control. FDA schedules PAIs based on internal resource allocation. Post-COVID backlogs remain in some program areas. Build 6 months of float between the planned qualification completion date and the planned first commercial production date.

Track clean room construction with a Gantt chart in gantt-chart.io and share it with your validation team, regulatory affairs team, and quality organization -- not just the construction team. The schedule is only useful if everyone who can cause a delay can see when their deliverables are due.

Start building your clean room construction Gantt chart at gantt-chart.io -- free, no account required.